The disclosure provides genetically engineered microorganisms capable of producing antigen-binding molecules. Additionally, the disclosure provides engineered microorganisms comprising one or more disrupted genes to strategically divert carbon flux away from undesirable products towards products, and optionally co-products, of interest. Further, the disclosure enables co-production of useful chemicals from gaseous substrates.

The present invention provides a microbial consortium comprising two or more microorganisms, compositions and kits comprising the same and uses thereof in methods of treating immune-related conditions.

Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.

Provided is a method for producing an organic substance from a syngas by microbial fermentation, wherein only the solid component can be efficiently separated from an organic substance-containing liquid obtained by microbial fermentation to reduce the content of microorganisms, etc. Disclosed is a method for producing an organic substance from a syngas containing carbon monoxide by microbial fermentation, which comprises a microbial fermentation step wherein the syngas is fed to a microbial fermenting vessel and a liquid containing an organic substance is obtained by microbial fermentation, a solid-liquid separation step wherein the organic substance-containing liquid is separated into a solid component containing microorganisms and a liquid component containing an organic substance, and an extraction step wherein the organic substance-containing liquid is extracted from the liquid component, wherein the organic substance-containing liquid is heated to 40° C. or higher and then subjected to a centrifugal separation operation.

Provided herein are methods of treating graft-versus-host disease in a subject by administering pharmaceutical compositions containing bacterial strains of the Clostridia class. Also described herein are exemplary human-derived bacteria belonging to the Clostridia class, combinations of which have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions, and are therefore useful for mitigating pathological immune responses. Pharmaceutical compositions containing these and/or related bacteria can be used to prevent and treat immune-mediated diseases such as graft-versus-host disease.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

The present disclosure belongs to the technical field of biomedicine, and provides use of Faecalibacterium prausnitzii in preparation of a medicine for treating pathological ventricular remodeling and/or heart failure following myocardial infarction. The Faecalibacterium prausnitzii can improve pathological ventricular remodeling and/or heart failure caused by myocardial infarction in experimental animals, resume the systolic function, reduce the cardiac fibrosis, and inhibit the pathological myocardial hypertrophy of mice with myocardial infarction. Furthermore, the inactivated Faecalibacterium prausnitzii has no such improvement effect.

Disclosed are methods related to culturing anaerobic bacteria in a microaerobic environment. The method comprises culturing in a microaerobic environment an anaerobic bacteria with an aerobic microorganism. The microaerobic environment may not require gas pre-treatment to remove trace O.sub.2. Also disclosed are methods related to producing a product, syngas fermentation, and gas valorization. The method comprises culturing in a microaerobic environment an anaerobic bacteria with an aerobic microorganism.

Provided herein, inter alia, are compositions of short chain fatty acid (SCFA)-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

The present invention provides a method for detecting and assaying Clostridium neurotoxins and identification of serotypes of botulinum neurotoxins in various food matrices and clinical samples. This method is also used for detection of BoNT inside the neuronal and epithelial cells. The method comprises detecting and assaying the presence of a Clostridium neurotoxin in a sample by: exposing the sample containing a Clostridium neurotoxin to a sample comprising a novel SNAMPXIN/SNAMP universal recombinant substrate fusion protein capable of producing a detectable FRET, following cleavage; detecting and assaying the presence of the Clostridium neurotoxin by measuring a change in the energy transfer or the luminescence signal; and detecting and assaying an electrophoretic mobility pattern of one or more cleaved protein bands or a degraded protein, using a high throughput automated system to identify the different serotypes of the Clostridium neurotoxin. SNAMPXIN/SNAMP is formed from parts of BoNT substrates SNAP-25 and VAMP.